ClinicalTrials.gg
CompletedNCT02980133Updated Nov 9, 2021Results posted

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

A Phase 3 interventional study of Fluticasone Propionate and Fluticasone Propionate/Salmeterol in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 118 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
841
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
12th of 146
841 · median 100
Started
2016
with 5 others
Phase 3
35 of 147
none open now
Registered
126th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 12th largest by enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2016, is one of 35 in phase 3, and was the 126th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study is to evaluate the safety and efficacy of fluticasone propionate and fluticasone propionate salmeterol in pediatric participants with a documented history of persistent asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of asthma as defined by the National Institutes of Health (NIH).
  • The participant has persistent asthma with a ≥50% and ≤90% of the value predicted for age, height, sex, and race at the screening visit (SV).
  • The participant's persistent asthma is stable and is currently being treated with stable asthma therapy for at least 30 days before the SV. Participants currently on a short-acting β2-agonist (SABA) only, regimen or as needed (PRN), are not eligible.
  • The participant has demonstrated ≥10% response to a bronchodilator from screening FEV1 within 30 minutes after 2 to 4 inhalations of albuterol/salbutamol.
  • The participant (with assistance from parents/legal guardians/caregivers, as needed) is able to perform technically acceptable lung function assessments by handheld device.
  • All participants must be able to replace their current SABA with albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) inhalation aerosol at the SV for use as needed for the duration of the study.

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The participant has a history of life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures.
  • The participant is pregnant or lactating or plans to become pregnant during the study period or within 30 days after the participant's last study-related visit.
  • The participant has a known to any , salmeterol, or any of the in the medicinal product (IMP) or rescue medication formulation (that is, lactose).
  • The participant has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (for example, ketoconazole, ritonavir, clarithromycin) within 30 days before the SV or plans to be treated with any strong inhibitor during the study.
  • The participant currently smokes or has a smoking history. The participant must not have used tobacco products within the past year (for example, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  • The participant has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV or has had any hospitalization for asthma within 2 months before the SV.
  • The participant has used medications within 30 days before the SV.
  • The participant has untreated oral candidiasis at the SV. Participants with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the run-in period.
  • The participant has a history of a positive test for , active virus, or infection.
  • The participant is an immediate relative of an employee of the clinical investigational center.
  • A member of the participant's household is participating in the study at the same time.
  • Vulnerable participants (that is, people kept in detention) are excluded from participation.

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
841 participants (actual)

Study arms

  • Placebo comparator
    Placebo MDPI

    Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.

    Drug: Placebo MDPI

  • Experimental
    Fp MDPI 25 mcg BID

    Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.

    Drug: Fluticasone Propionate

  • Experimental
    Fp MDPI 50 mcg BID

    Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.

    Drug: Fluticasone Propionate

  • Experimental
    FS MDPI 50/12.5 mcg BID

    Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.

    Drug: Fluticasone Propionate/Salmeterol

Interventions

  • Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.

  • DrugFluticasone Propionate/Salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.

  • DrugPlacebo MDPI

    Matching placebo was administered via MDPI per the schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \[Day 1\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (±10 minutes) postdose lung function assessments on Week 12 at the investigational center.

    Time frame: Baseline, Week 12

  2. For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.

    Time frame: Baseline, Week 1 to 12

  2. Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12

    Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \[Day 1\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).

    Time frame: Baseline, Week 1 to 12

  3. Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12

    Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.

    Time frame: Baseline, Week 1 to 12

  4. Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period

    C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score ≤5) to complete control of asthma (score ≥25), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.

    Time frame: Baseline, Week 1 to 12

  5. Time to First Onset of Effect

    The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \[HFA MDI\] \[90 mcg ex actuator\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.

    Time frame: Baseline up to Week 12

  6. Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period

    Time frame: Baseline up to Week 12

07

Results

Posted Mar 18, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Started209211210211
Received at least 1 dose of study drug209211208211
Completed202206203205
Not completed7576
Withdrew: Other than specified1122
Withdrew: Lost to follow-up0013
Withdrew: Protocol violation0100
Withdrew: Withdrawal by parent/guardian6331
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryFor FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \[Day 1\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (±10 minutes) postdose lung function assessments on Week 12 at the investigational center.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent predicted of FEV1
For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12
percent predicted of FEV1Fp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 1216.8 ± 1.3216.4 ± 1.3218.2 ± 1.29
Statistical analysis
  • Fp MDPI 50 mcg BID vs FS MDPI 50/12.5 mcg BID · ANCOVA · p = 0.285 (Threshold for significance at 0.05 level.) · Ls mean difference: 1.9 · 95% CI -1.6 to 5.3
PrimaryFor Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent predicted of FEV1
For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12
percent predicted of FEV1Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BID
For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 127.3 ± 1.1013.3 ± 1.0914.2 ± 1.10
Statistical analysis
  • Placebo MDPI vs Fp MDPI 25 mcg BID · ANCOVA · p = <0.001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: 6.0 · 95% CI 3.2 to 8.8
  • Placebo MDPI vs Fp MDPI 50 mcg BID · ANCOVA · p = <0.001 (Threshold for significance at 0.05 level.) · Ls mean difference: 7.0 · 95% CI 4.1 to 9.8
SecondaryChange From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.

Time frame:
Baseline, Week 1 to 12
Reported as:
Least squares mean · liters/minute
Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period
liters/minutePlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period12.3 ± 2.6528.9 ± 2.6226.3 ± 2.6432.0 ± 2.61
SecondaryChange From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12

Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \[Day 1\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).

Time frame:
Baseline, Week 1 to 12
Reported as:
Least squares mean · inhalations
Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12
inhalationsPlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12-0.2 ± 0.05-0.4 ± 0.05-0.5 ± 0.05-0.4 ± 0.05
SecondaryChange From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12

Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.

Time frame:
Baseline, Week 1 to 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12
units on a scalePlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12-0.1 ± 0.02-0.2 ± 0.02-0.2 ± 0.02-0.2 ± 0.02
SecondaryChange From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period

C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score ≤5) to complete control of asthma (score ≥25), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.

Time frame:
Baseline, Week 1 to 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period
units on a scalePlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period4.5 ± 0.215.1 ± 0.215.5 ± 0.215.4 ± 0.21
SecondaryTime to First Onset of Effect

The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \[HFA MDI\] \[90 mcg ex actuator\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.

Time frame:
Baseline up to Week 12
Reported as:
Median · days
Time to First Onset of Effect
daysPlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Time to First Onset of Effect20.0 (5.0 to NA)NA (3.0 to NA)2.0 (2.0 to 2.0)6.0 (2.0 to NA)
SecondaryPercentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period
Time frame:
Baseline up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period
percentage of participantsPlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period6212

Adverse events

Collected over Baseline up to Week 13. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo MDPI0/209 (0%)1/209 (0.5%)11/209 (5.3%)
Fp MDPI 25 mcg BID0/211 (0%)2/211 (0.9%)8/211 (3.8%)
Fp MDPI 50 mcg BID0/208 (0%)1/208 (0.5%)11/208 (5.3%)
FS MDPI 50/12.5 mcg BID0/211 (0%)4/211 (1.9%)9/211 (4.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
Disruptive mood dysregulation disorderPsychiatric disorders0/2090/2111/2080/211
Respiratory tract infection viralInfections and infestations1/2090/2110/2080/211
AsthmaRespiratory, thoracic and mediastinal disorders1/2091/2110/2080/211
LymphadenitisBlood and lymphatic system disorders0/2090/2110/2081/211
PyrexiaGeneral disorders0/2090/2110/2081/211
Pneumonia mycoplasmalInfections and infestations0/2091/2110/2080/211
HeadacheNervous system disorders0/2090/2110/2081/211
Partial seizuresNervous system disorders0/2090/2110/2081/211
Most frequent other events
Most frequent other events
EventPlacebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BID
NasopharyngitisInfections and infestations11/2098/21111/2089/211

Baseline characteristics

Intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BIDTotal
Mean8.5 ± 1.988.7 ± 1.838.5 ± 1.948.4 ± 2.058.5 ± 1.95
Sex: Female, Male
Sex: Female, Male(Participants)Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BIDTotal
Female79748091324
Male130137130120517
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BIDTotal
White172168171172683
Black or African American33413229135
Asian10236
American Indian or Alaska Native01203
Native Hawaiian or Other Pacific Islander10001
Other213713
At-Home Baseline Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
At-Home Baseline Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)(percent predicted of FEV1)Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BIDTotal
Mean68.8 ± 9.7069.6 ± 9.6869.6 ± 9.4769.9 ± 9.1569.5 ± 9.49
In-Clinic Baseline Percent Predicted FEV1
In-Clinic Baseline Percent Predicted FEV1(percent predicted of FEV1)Placebo MDPIFp MDPI 25 mcg BIDFp MDPI 50 mcg BIDFS MDPI 50/12.5 mcg BIDTotal
Mean74.9 ± 14.5873.0 ± 13.4372.9 ± 13.0074.1 ± 15.0273.7 ± 14.03
08

Study locations

118 sites
  • Teva Investigational Site 13881
    Birmingham, Alabama 35209, United States
  • Teva Investigational Site 13883
    Little Rock, Arkansas 72205, United States
  • Teva Investigational Site 13906
    Bakersfield, California 93301, United States
  • Teva Investigational Site 14615
    Corona, California 92883, United States
  • Teva Investigational Site 13892
    Downey, California 90241, United States
  • Teva Investigational Site 13875
    Fountain Valley, California 92708, United States
  • Teva Investigational Site 13904
    Huntington Beach, California 92647 6818, United States
  • Teva Investigational Site 13877
    Huntington Beach, California 92648, United States
  • Teva Investigational Site 14668
    Long Beach, California 90806, United States
  • Teva Investigational Site 13914
    Napa, California 94558, United States
  • Teva Investigational Site 13918
    Paramount, California 90723, United States
  • Teva Investigational Site 14618
    Rolling Hills Estates, California 90274, United States
  • Teva Investigational Site 13912
    Roseville, California 95661, United States
  • Teva Investigational Site 13847
    Stockton, California 95207, United States
  • Teva Investigational Site 13848
    Thousand Oaks, California 91360, United States
  • Teva Investigational Site 13856
    Centennial, Colorado 80112, United States
  • Teva Investigational Site 13910
    Colorado Springs, Colorado 80907, United States
  • Teva Investigational Site 13868
    Longmont, Colorado 80501, United States
  • Teva Investigational Site 13913
    Chiefland, Florida 32626, United States
  • Teva Investigational Site 14616
    DeLand, Florida 32720, United States
  • Teva Investigational Site 13909
    Homestead, Florida 33030, United States
  • Teva Investigational Site 13857
    Loxahatchee Groves, Florida 33470, United States
  • Teva Investigational Site 13870
    Miami Lakes, Florida 33014, United States
  • Teva Investigational Site 14617
    Miami Lakes, Florida 33015, United States
  • Teva Investigational Site 13916
    Miami Springs, Florida 33185, United States
  • Teva Investigational Site 13872
    Miami, Florida 33134, United States
  • Teva Investigational Site 13907
    Miami, Florida 33134, United States
  • Teva Investigational Site 13893
    Miami, Florida 33142, United States
  • Teva Investigational Site 13886
    Miami, Florida 33155, United States
  • Teva Investigational Site 13899
    Miami, Florida 33175, United States
  • Teva Investigational Site 13864
    Miami, Florida 33176, United States
  • Teva Investigational Site 13880
    Miami, Florida 33176, United States
  • Teva Investigational Site 13911
    Ocala, Florida 34471, United States
  • Teva Investigational Site 13876
    Palmetto Bay, Florida 33157, United States
  • Teva Investigational Site 13844
    Winter Park, Florida 32789, United States
  • Teva Investigational Site 13866
    Gainesville, Georgia 30501, United States
  • Teva Investigational Site 13858
    Savannah, Georgia 31406, United States
  • Teva Investigational Site 13896
    Eagle, Idaho 83616, United States
  • Teva Investigational Site 13903
    Idaho Falls, Idaho 83402, United States
  • Teva Investigational Site 13882
    Springfield, Illinois 62704, United States
  • Teva Investigational Site 13887
    Overland Park, Kansas 66210, United States
  • Teva Investigational Site 13851
    Owensboro, Kentucky 42301, United States
  • Teva Investigational Site 13849
    Rockville, Maryland 20850, United States
  • Teva Investigational Site 13865
    Columbia, Missouri 65203, United States
  • Teva Investigational Site 13885
    Columbia, Missouri 65203, United States
  • Teva Investigational Site 13891
    Missoula, Montana 59808, United States
  • Teva Investigational Site 13897
    Ocean City, New Jersey 07712, United States
  • Teva Investigational Site 13854
    Verona, New Jersey 07044, United States
  • Teva Investigational Site 13908
    Watertown, New York 13601, United States
  • Teva Investigational Site 13890
    Charlotte, North Carolina 28277, United States
  • Teva Investigational Site 13863
    Raleigh, North Carolina 27607, United States
  • Teva Investigational Site 13855
    Canton, Ohio 44718, United States
  • Teva Investigational Site 13905
    Milford, Ohio 45150, United States
  • Teva Investigational Site 13852
    Oklahoma City, Oklahoma 73112, United States
  • Teva Investigational Site 13879
    Oklahoma City, Oklahoma 73112, United States
  • Teva Investigational Site 13884
    Oklahoma City, Oklahoma 73120, United States
  • Teva Investigational Site 13860
    Tulsa, Oklahoma 74136, United States
  • Teva Investigational Site 13894
    Tulsa, Oklahoma 74136, United States
  • Teva Investigational Site 13861
    Medford, Oregon 97504, United States
  • Teva Investigational Site 13874
    Pittsburgh, Pennsylvania 15241, United States
  • Teva Investigational Site 13895
    Scottdale, Pennsylvania 15683, United States
  • Teva Investigational Site 13888
    Providence, Rhode Island 02909, United States
  • Teva Investigational Site 13871
    Charleston, South Carolina 29407, United States
  • Teva Investigational Site 13889
    Charleston, South Carolina 29414, United States
  • Teva Investigational Site 13853
    Spartanburg, South Carolina 29303, United States
  • Teva Investigational Site 14671
    Summerville, South Carolina 29483, United States
  • Teva Investigational Site 13898
    Baytown, Texas 77521, United States
  • Teva Investigational Site 14673
    Boerne, Texas 78006, United States
  • Teva Investigational Site 13867
    El Paso, Texas 79903, United States
  • Teva Investigational Site 13902
    Killeen, Texas 76542-0969, United States
  • Teva Investigational Site 13846
    Live Oak, Texas 78233, United States
  • Teva Investigational Site 13878
    San Antonio, Texas 78229, United States
  • Teva Investigational Site 14672
    San Antonio, Texas 78229, United States
  • Teva Investigational Site 13917
    San Antonio, Texas 78251, United States
  • Teva Investigational Site 13845
    Waco, Texas 76712, United States
  • Teva Investigational Site 13850
    Richmond, Virginia 23223, United States
  • Teva Investigational Site 13915
    Bellingham, Washington 98225, United States
  • Teva Investigational Site 81041
    Kutaisi, 4600, Georgia
  • Teva Investigational Site 81047
    Tbilisi, 0119, Georgia
  • Teva Investigational Site 81046
    Tbilisi, 0141, Georgia
  • Teva Investigational Site 81044
    Tbilisi, 0159, Georgia
  • Teva Investigational Site 81040
    Tbilisi, 0160, Georgia
  • Teva Investigational Site 81045
    Tbilisi, 0171, Georgia
  • Teva Investigational Site 81042
    Tbilisi, 0179, Georgia
  • Teva Investigational Site 81043
    Tbilisi, 0186, Georgia
  • Teva Investigational Site 51277
    Budapest, 1083, Hungary
  • Teva Investigational Site 51278
    Budapest, 1094, Hungary
  • Teva Investigational Site 51272
    Budapest, H-1021, Hungary
  • Teva Investigational Site 51279
    Debrecen, 4032, Hungary
  • Teva Investigational Site 51271
    Dombovar, 7200, Hungary
  • Teva Investigational Site 51269
    Gyor, 9023, Hungary
  • Teva Investigational Site 51274
    Kaposvar, 7400, Hungary
  • Teva Investigational Site 51270
    Miskolc, 3526, Hungary
  • Teva Investigational Site 51276
    Szeged, 6720, Hungary
  • Teva Investigational Site 51273
    Szigetvar, 7900, Hungary
  • Teva Investigational Site 50444
    Moscow, 125412, Russian Federation
  • Teva Investigational Site 50446
    Perm, 614066, Russian Federation
  • Teva Investigational Site 50445
    Saint Petersburg, 196240, Russian Federation
  • Teva Investigational Site 50443
    Saint Petersburg, 196657, Russian Federation
  • Teva Investigational Site 50442
    Saint-Petersburg, 191144, Russian Federation

Showing the first 100 of 118 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2019, 27 months.

Results were first posted in Mar 2020, 11 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Dec 2, 2016
StartActual
Dec 28, 2016
Primary completionActual
Apr 7, 2019
CompletionActual
Apr 13, 2019
Results first posted
Mar 18, 2020
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02980133
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Dec 28, 2016
Primary completion
Apr 7, 2019
Completion
Apr 13, 2019
Results posted
Mar 18, 2020
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion